BACKGROUND: Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer. PATIENTS AND METHODS: Patients received bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of an every-21-day cycle, along with PLD 30 mg/m2 on day 4. The primary objective was to evaluate the response rate of this combination, while secondary objectives were to obtain further safety data about this combination, to evaluate the time to disease progression (TTP), and to evaluate response by the breast cancer subtype. RESULTS: One of 12 evaluable patients had a partial response (8%), while 3 (25%) had stable disease. At 26 months follow-up, the median overall survival was 4.3 months (95% CI, 1.2-26.2) and the median TTP was 1.3 months (95% CI, 0.8-14.0 months). The combination was well tolerated, with the most common events including low-grade nausea and vomiting, neutropenia, and neuropathy, and no cardiac toxicity was seen. Of the 7 tumors subtyped, no association was seen between intrinsic subtype or receptor status and response. CONCLUSION: The combination of PLD and bortezomib was well tolerated but has minimal activity in heavily pretreated unselected metastatic breast cancer.
BACKGROUND: Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer. PATIENTS AND METHODS: Patients received bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of an every-21-day cycle, along with PLD 30 mg/m2 on day 4. The primary objective was to evaluate the response rate of this combination, while secondary objectives were to obtain further safety data about this combination, to evaluate the time to disease progression (TTP), and to evaluate response by the breast cancer subtype. RESULTS: One of 12 evaluable patients had a partial response (8%), while 3 (25%) had stable disease. At 26 months follow-up, the median overall survival was 4.3 months (95% CI, 1.2-26.2) and the median TTP was 1.3 months (95% CI, 0.8-14.0 months). The combination was well tolerated, with the most common events including low-grade nausea and vomiting, neutropenia, and neuropathy, and no cardiac toxicity was seen. Of the 7 tumors subtyped, no association was seen between intrinsic subtype or receptor status and response. CONCLUSION: The combination of PLD and bortezomib was well tolerated but has minimal activity in heavily pretreated unselected metastatic breast cancer.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Robert Z Orlowski; Arnon Nagler; Pieter Sonneveld; Joan Bladé; Roman Hajek; Andrew Spencer; Jesús San Miguel; Tadeusz Robak; Anna Dmoszynska; Noemi Horvath; Ivan Spicka; Heather J Sutherland; Alexander N Suvorov; Sen H Zhuang; Trilok Parekh; Liang Xiu; Zhilong Yuan; Wayne Rackoff; Jean-Luc Harousseau Journal: J Clin Oncol Date: 2007-08-06 Impact factor: 44.544
Authors: C H Yang; A M Gonzalez-Angulo; J M Reuben; D J Booser; L Pusztai; S Krishnamurthy; D Esseltine; J Stec; K R Broglio; R Islam; G N Hortobagyi; M Cristofanilli Journal: Ann Oncol Date: 2006-01-10 Impact factor: 32.976
Authors: Charlton Cooper; Guang-Yu Liu; Yu-Lian Niu; Sylvia Santos; Leigh C Murphy; Peter H Watson Journal: Clin Cancer Res Date: 2004-12-15 Impact factor: 12.531
Authors: Michael P Fanucchi; Frank V Fossella; Robert Belt; Ronald Natale; Panos Fidias; David P Carbone; Ramaswamy Govindan; Luis E Raez; Francisco Robert; Maria Ribeiro; Wallace Akerley; Karen Kelly; Steven A Limentani; Jeffrey Crawford; Hans-Joachim Reimers; Rita Axelrod; Oscar Kashala; Shihong Sheng; Joan H Schiller Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544
Authors: George W Small; Yue Y Shi; Natalie A Edmund; Sivagurunathan Somasundaram; Dominic T Moore; Robert Z Orlowski Journal: Mol Pharmacol Date: 2004-09-24 Impact factor: 4.436
Authors: Teru Hideshima; Constantine Mitsiades; Masaharu Akiyama; Toshiaki Hayashi; Dharminder Chauhan; Paul Richardson; Robert Schlossman; Klaus Podar; Nikhil C Munshi; Nicholas Mitsiades; Kenneth C Anderson Journal: Blood Date: 2002-09-26 Impact factor: 22.113
Authors: E Claire Dees; Bert H O'Neil; Celeste M Lindley; Frances Collichio; Lisa A Carey; Jason Collins; William J Riordan; Anastasia Ivanova; Dixie Esseltine; Robert Z Orlowski Journal: Cancer Chemother Pharmacol Date: 2008-03-08 Impact factor: 3.333